Compare TRIB & POM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | POM |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | Ireland | China |
| Employees | N/A | 165 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 11.9M |
| IPO Year | 1996 | N/A |
| Metric | TRIB | POM |
|---|---|---|
| Price | $0.39 | $1.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 584.1K |
| Earning Date | 05-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.51 | N/A |
| Revenue Next Year | $13.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.06 |
| 52 Week High | $3.44 | $6.43 |
| Indicator | TRIB | POM |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 74.39 |
| Support Level | $0.31 | $0.17 |
| Resistance Level | $0.75 | $5.00 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 24.21 | 87.04 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.